PharmaCyte Biotech, Inc.
For the period ended Apr 30, 2026. Filed Jul 29, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jul 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PharmaCyte Biotech, Inc. | |
| July 29, 2026 | By: /s/ Joshua N. Silverman |
|---|---|
| Joshua N. Silverman Chief Executive Officer | |
| (Duly Authorized Officer and Principal Executive Officer) | |
| July 29, 2026 | By: /s/ Carlos A Trujillo Carlos A. Trujillo Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) |
Pursuant to the requirements of the Exchange Act, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| July 29, 2026 | By: /s/ Joshua N. Silverman Joshua N. Silverman Chief Executive Officer, Chairman of the Board and Director (Principal Executive Officer) |
|---|---|
| July 29, 2026 | By: /s/ Carlos A. Trujillo Carlos A. Trujillo Chief Financial Officer (Principal Financial and Accounting Officer) |
| July 29, 2026 | By: /s/ Jonathan L. Schechter Jonathan L. Schechter, Director |
| July 29, 2026 | By: /s/ Robert Weinstein Robert Weinstein, Director |
| July 29, 2026 | By: /s/ Michael M. Abecassis |
| Michael M. Abecassis, Director | |
| July 29, 2026 | By: /s/ Wayne R. Walker |
| Wayne R. Walker, Director |
SUPPLEMENTAL INFORMATION TO BE FURNISHED WITH REPORTS FILED
PURSUANT TO SECTION 15(d) OF THE ACT BY REGISTRANTS
WHICH HAVE NOT REGISTERED SECURITIES PURSUANT TO SECTION 12 OF THE ACT
The registrant has not sent to its security holders any annual report covering the registrant’s fiscal year ended April 30, 2026.
CONTENTS
| Report of Independent Registered Public Accounting Firm - CBIZ CPAs P.C. (PCAOB Auditor ID: 199) | F-2 |
|---|---|
| Consolidated Balance Sheets as of April 30, 2026, and 2025 | F-4 |
| Consolidated Statements of Operations for the Years Ended April 30, 2026, and 2025 | F-5 |
| Consolidated Statements of Comprehensive Income (Loss) for the Years Ended April 30, 2026, and 2025 | F-6 |
| Consolidated Statements of Changes in Temporary Equity and Stockholders’ Equity for the Years Ended April 30, 2026, and 2025 | F-7 |
| Consolidated Statements of Cash Flows for the Years Ended April 30, 2026, and 2025 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
340 Mount Kemble Ave Suite 210N Morristown, NJ 07960 P: 973.929.3500
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.